Rankings / Metabolic Health

Aspirin (low-dose)

Metabolic Health · Irreversible COX-1 inhibitor

Tier B

Reviewed by Read Off Label · Last reviewed · How we grade

cox-pathwayotc
6.8 / 10
Tier B
Ev 8 Bn 8 Sf 5

Bottom line

Read Off Label grades Aspirin (low-dose) as B (6.8/10) based on strong evidence, strong benefit magnitude, and a med-risk safety profile.

USPSTF 2022 updated: aspirin for primary prevention in ages 40-59 with ≥10% 10-yr ASCVD risk is a Grade C (individualized decision); against for ≥60.

Studied, labeled, or reported-use context: 75-100 mg/day PO (81 mg standard in US) — OTC; not individualized guidance.

What the evidence says

USPSTF 2022 updated: aspirin for primary prevention in ages 40-59 with ≥10% 10-yr ASCVD risk is a Grade C (individualized decision); against for ≥60. Still a cornerstone in secondary prevention. Primary-prevention trials in most healthy adults show bleeding risk without a net outcome benefit; guidelines restrict use to selected risk profiles. ASPREE healthspan analysis (Age and Ageing, Jul 2026; n=19,114, median 4.7 years): loss of healthspan — defined as first occurrence of cardiovascular disease, diabetes, dementia, cancer, or death — occurred at 82.1 events per 1,000 person-years on 100 mg daily aspirin versus 82.7 on placebo, with no evidence of a substantial difference. This extends the existing primary-prevention picture from event endpoints to a composite healthspan endpoint in initially healthy older adults; it does not bear on secondary prevention.

Mechanism

Irreversible acetylation of platelet COX-1 for lifetime of platelet; prevents thromboxane A2 synthesis → reduced platelet aggregation

Studied, labeled, or reported dose & route

75-100 mg/day PO (81 mg standard in US)

This records doses and routes described in studies, approved labeling, clinical practice, or documented use. It is not individualized guidance and does not establish safety; context changes with indication, formulation, health history, monitoring, and other medicines.

Citations

A link means the source informed this entry; it does not mean every claim on the page comes from that source. If a citation looks wrong or you want a claim re-checked, send a correction.

Common questions

What does the evidence show about Aspirin (low-dose)'s effects?
Read Off Label rates the evidence for Aspirin (low-dose) as Strong and the benefit magnitude as strong, producing an overall grade of B (6.8/10). USPSTF 2022 updated: aspirin for primary prevention in ages 40-59 with ≥10% 10-yr ASCVD risk is a Grade C (individualized decision); against for ≥60.
What safety findings are reported for Aspirin (low-dose)?
Aspirin (low-dose) has a med risk profile in the database. Med (GI bleeding — dose-dependent; rare intracranial hemorrhage; Reye's syndrome in children) Legal status: OTC.
What doses or routes are reported for Aspirin (low-dose)?
75-100 mg/day PO (81 mg standard in US) This is context from studies, approved labeling, clinical practice, or documented use; it is not individualized guidance and does not establish safety.
How does Aspirin (low-dose) work?
Irreversible acetylation of platelet COX-1 for lifetime of platelet; prevents thromboxane A2 synthesis → reduced platelet aggregation

This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.